Core Viewpoint - The merger of DSM and Firmenich has reached a significant milestone with the announcement of the sale of its Animal Nutrition and Health (ANH) business for approximately €2.2 billion, marking a total divestment value of €3.7 billion when including previously sold feed enzyme business [2][3][9]. Group 1: Transaction Details - The enterprise value of the ANH business sale is €2.2 billion, which includes a contingent consideration of up to €500 million [3]. - DSM-Firmenich retains a 20% equity stake in the ANH business post-divestment, indicating confidence in the future value of this asset [4]. - The ANH business is a leading provider of scientific animal nutrition and health solutions, covering a full range of products from vitamins to feed additives [5]. Group 2: Business Overview - The ANH business is projected to have an annualized net sales of approximately €3.5 billion in 2025 and employs around 8,000 people [6]. - Key technologies such as Bovaer® (a methane-reducing feed additive) and Veramaris™ (a joint venture for algal Omega-3) will remain within the DSM-Firmenich portfolio [7]. Group 3: Strategic Implications - The divestment will occur in two phases, splitting the ANH business into two independent companies: a Solutions Company and an Essential Products Company, both headquartered in Kaiseraugst, Switzerland [8]. - The valuation of the ANH business is based on normalized adjusted EBITDA, implying an EV/EBITDA multiple of approximately 7 times, which increases to 10 times when including the feed enzyme business [9]. Group 4: Financial Outlook - DSM-Firmenich expects to receive approximately €1.2 billion from the transaction, including around €600 million in net cash proceeds, €500 million in debt and liability transfers, and €100 million in supplier loan notes [9]. - The transaction is anticipated to be completed by the end of 2026, pending regulatory approvals and employee consultation processes [9]. Group 5: Market Reactions - Following a meeting with DSM-Firmenich's CFO, Deutsche Bank lowered the target price from €120 to €105 while maintaining a "buy" rating, primarily due to a downward revision of EBITDA forecasts for 2025-2027 by 1-6% [10][11]. - Analysts emphasize the need for DSM-Firmenich to restore organic sales growth and improve profit margins to achieve substantial value re-evaluation [11].